Centre Hospitalier Universitaire De La Reunion

Research site

France Allee Des Topazes, Cs 11021, 97400, France

22 trials recruiting
Dermatitis atopic · Plasma cell myeloma · Retinoblastoma
Adults and children

About Specializations

Centre Hospitalier Universitaire De La Reunion in France specialises in clinical trials of conditions such as Dermatitis atopic, Plasma cell myeloma, Retinoblastoma, Anaplastic large cell lymphoma T- and null-cell types, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Allee Des Topazes, Cs 1102197400France

Open in maps ↗

Recruiting now: 22 trials
Conditions studied: 52

More sites in France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

45 clinical trials

Acute promyelocytic leukaemia

Recruiting

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo

France

Participants:0–17 years
Substances:Arsenic Trioxide
Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Intergroupe Francophone Du Myelome

Contact Research Centre

Triple negative breast cancer

Recruiting

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Unicancer

Contact Research Centre

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Respiratory distress

Recruiting

Study on the Effect of Rocuronium Bromide, Sugammadex, and Suxamethonium Chloride for Adults with Respiratory Distress Requiring Emergency Tracheal Intubation

Registered drugNo placebo

Study on the Effect of Rocuronium Bromide, Sugammadex, and Suxamethonium Chloride for Adults with Respiratory Distress Requiring Emergency Tracheal Intubation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Rocuronium Bromide
Sponsor:Centre Hospitalier Universitaire De Bordeaux

Contact Research Centre

Subarachnoid haemorrhage

Recruiting

Study on Milrinone for Preventing Delayed Brain Ischemia in Patients with Severe Subarachnoid Hemorrhage

Registered drug

Study on Milrinone for Preventing Delayed Brain Ischemia in Patients with Severe Subarachnoid Hemorrhage

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Glucose Monohydrate
Sponsor:Centre Hospitalier Universitaire De Toulouse

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cenerimod
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites